http://www.dailymail.co.uk/health/article-2225293/Pill-halts-Alzheimers-years.html
I know ... not an article about Parkinson's disease but Alzheimer. It is supposed to halt progression of AD with 90 % !!! We are now almost 2013 ... people taking this since 2006 are still functioning normal and going to work and this having AD for 6 years. How amazing is that ?!?!?!
We still need to see the results in a big phase III trial. But if succesful the pills will be available in 2017. Fantastic !!! For the first time something has been found to firmly arrest the progression of a CNS disease.
Tau protein does have a certain connection with PD too. So who knows this drug might in the end also prove to be beneficial of PD.
http://www.ncbi.nlm.nih.gov/pubmed/20678581
http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(11)70130-2/fulltext
In fact, LMTX is an improved version of Rember. Rember is basically methylene blue. And I found this article about mythelene blue:
http://www.sciencedaily.com/releases/2008/08/080818101335.htm
This means that LMTX could possibly also be a "cure" for PD !!!
I too read the article and we will no doubt have friends calling tomorrow who say, yet again..................hey, they have found a cure!!!
We have heard that so many times over the last 15 years, so, when it does happen we will believe it, until then unfortunately it's probably status quo for longer than most of us would wish for. However, I do hope that this is THE one that actually works.
We have heard that so many times over the last 15 years, so, when it does happen we will believe it, until then unfortunately it's probably status quo for longer than most of us would wish for. However, I do hope that this is THE one that actually works.
I agree with you, Benji. But at least this is the first med ever that I know about that in a clinical phase II trial for Alzheimer resulted in such spectaculair results. People on Rember could work from 2006 to 2012. That's amazing. Alzheimer goes quite fast. So the Rember must do something good. However, it was not been tested on PD patients. But this is really hope giving for AD patients. And considering it works on the mitochondrial level, this could possibly also be very hope giving for PD patients. I will not be surprised if many PD patients will take LMTX once it gets on the shelves, even before clinical trials on PD patients confirm whether LMTX is beneficial for PD or not.
I found this on wikipedia (http://en.wikipedia.org/wiki/Rember):
"A larger Phase 3 trial is planned for 2009 with an idea to see whether methylene blue can prevent the formation of the disease in the first place.[7] TauRx are also looking into starting a trial of the drug on patients suffering from Parkinson's disease; as methylene blue also has effects on the synuclein fibres in the brain.[8]"
Maybe someone knows more about these trials for PD ? Maybe the research team here ?
I found this on wikipedia (http://en.wikipedia.org/wiki/Rember):
"A larger Phase 3 trial is planned for 2009 with an idea to see whether methylene blue can prevent the formation of the disease in the first place.[7] TauRx are also looking into starting a trial of the drug on patients suffering from Parkinson's disease; as methylene blue also has effects on the synuclein fibres in the brain.[8]"
Maybe someone knows more about these trials for PD ? Maybe the research team here ?
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091255/
In summary, we have identified a novel neuroprotective strategy represented by MB in the present study. We have demonstrated that MB could function as an electron carrier and provide an alternative electron transfer along ETC, avoid ROS overproduction induced by ETC blockage, and maintain mitochondrial function. We have tested this novel neuroprotective strategy in two animal models of neurological diseases. In an animal model of Parkinsonism, MB was able to attenuate rotenone-induced motor deficits and nigral-dopaminergic neuronal degeneration. In an ischemic stroke model, MB significantly reduced cerebral ischemia reperfusion damage. Considering that MB has been in clinical use for over a century with few known side effects, the identified novel neuroprotective strategy of alternative electron transfer is now ready for testing in clinical settings and might lead to the discovery of promising treatments for the mitochondria dysfunction-related neurological diseases, such as PD and stroke.
In summary, we have identified a novel neuroprotective strategy represented by MB in the present study. We have demonstrated that MB could function as an electron carrier and provide an alternative electron transfer along ETC, avoid ROS overproduction induced by ETC blockage, and maintain mitochondrial function. We have tested this novel neuroprotective strategy in two animal models of neurological diseases. In an animal model of Parkinsonism, MB was able to attenuate rotenone-induced motor deficits and nigral-dopaminergic neuronal degeneration. In an ischemic stroke model, MB significantly reduced cerebral ischemia reperfusion damage. Considering that MB has been in clinical use for over a century with few known side effects, the identified novel neuroprotective strategy of alternative electron transfer is now ready for testing in clinical settings and might lead to the discovery of promising treatments for the mitochondria dysfunction-related neurological diseases, such as PD and stroke.
Hi MisterX
I found this interesting page on the TauRx website which I think shows that they are starting Phase 1 trials of LMTX in Parkinson's:
http://taurx.com/pipeline/
It also looks as though they have other drugs for Parkinson's in the pipeline too.
Best wishes
Claire
(Research team)
I found this interesting page on the TauRx website which I think shows that they are starting Phase 1 trials of LMTX in Parkinson's:
http://taurx.com/pipeline/
It also looks as though they have other drugs for Parkinson's in the pipeline too.
Best wishes
Claire
(Research team)
Claire,
Thank you for the info. I was really looking for LMTX tests for Parkinson. I am happy they are already in clinical phase I with it. If the Alzheimer clinical trial III is positive, something which I really believe in, then in 4 years LMTX will be sold for Alzheimer. By then, I guess clinical phase II of LMTX in PD will already have given indications whether LMTX is beneficial for PD or not, as well as the optimal dosis. If so, then people with PD will probably get LMTX off label too in 4 years from now.
Thank you for the info. I was really looking for LMTX tests for Parkinson. I am happy they are already in clinical phase I with it. If the Alzheimer clinical trial III is positive, something which I really believe in, then in 4 years LMTX will be sold for Alzheimer. By then, I guess clinical phase II of LMTX in PD will already have given indications whether LMTX is beneficial for PD or not, as well as the optimal dosis. If so, then people with PD will probably get LMTX off label too in 4 years from now.
Some more on TauRx and Alzheimer ... the article shows how badly science is conducted:
http://online.wsj.com/article/SB10000872396390443624204578060941988428604.html
http://online.wsj.com/article/SB10000872396390443624204578060941988428604.html
A video presentation on rember/LMTX and it's impressive result on Alzheimer:
http://view6.workcast.net/?pak=1839740923512880
The thing that shocked me most is to hear that despite the fact that it was known very well that there was a very strong correlation between amount of tau tangles and amount of dementia, the AD community has almost only focused on the beta amyloid theory. I thought scientist would be a bit smarter than this. I never like people blindly following mainstream popular ideas.
Another interesting thing is that LMTX can probably almost "cure" (slow down) a huge amount of other neurodegenerative diseases. And the presenter confirmed Parkinson's disease is one of the diseases LMTX might be capable of arresting.
In october 2015 the clinical phase III results of LMTX in Alzheimer will be known. Given the impressive result of the clinical phase II I have no reason do doubt this trial will go well and in 2016 I guess LMTX will be available in the drug store. This means that people with Parkinson's disease can have LMTX off-label in 2016.
http://view6.workcast.net/?pak=1839740923512880
The thing that shocked me most is to hear that despite the fact that it was known very well that there was a very strong correlation between amount of tau tangles and amount of dementia, the AD community has almost only focused on the beta amyloid theory. I thought scientist would be a bit smarter than this. I never like people blindly following mainstream popular ideas.
Another interesting thing is that LMTX can probably almost "cure" (slow down) a huge amount of other neurodegenerative diseases. And the presenter confirmed Parkinson's disease is one of the diseases LMTX might be capable of arresting.
In october 2015 the clinical phase III results of LMTX in Alzheimer will be known. Given the impressive result of the clinical phase II I have no reason do doubt this trial will go well and in 2016 I guess LMTX will be available in the drug store. This means that people with Parkinson's disease can have LMTX off-label in 2016.